Stocks of the Hour: Immutep, Lepidico, Mithril Silver and Gold

ShareCafe09-16



 


Immutep (ASX:IMM) has reported that eftilagimod alpha (efti) combined with MSD's KEYTRUDA® shows high efficacy and a favourable safety profile for treating head and neck cancer. The TACTI-003 trial revealed a 31.0% overall response rate in patients with high PD-L1 expression, highlighting efti’s potential to improve treatment outcomes without added toxicity. Shares are trading 12.5 per cent lower at 35 cents.

Lepidico’s (ASX:LPD) Trelavour Hard Rock Project has been named a Nationally Significant Infrastructure Project by the UK Government, endorsing its lithium processing technologies. The £9 million demonstration plant, using Lepidico’s L-Max® and LOH-Max® technologies, is nearing completion and will produce battery-grade lithium hydroxide. Shares are trading 50 per cent higher at 0.3 cents.

Mithril Silver and Gold (ASX:MTH) LiDAR survey of the Copalquin District in Mexico uncovered over 100 historic mining sites, revealing extensive geology and structural details. This discovery highlights the district’s potential as a major gold-silver system. The company is advancing its drilling and TSXV listing efforts. Shares are trading 40 per cent higher at 17.5 cents.  
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment